Dioxin-like compounds are not associated with bone strength measured by ultrasonography in Inuit women from Nunavik (Canada): results of a cross-sectional study

Alexandra-Cristina Paunescu1, Pierre Ayotte1,2*, Éric Dewailly1 and Sylvie Dodin1

1Axe santé publique et pratiques optimales en santé, Centre de recherche du CHU de Québec, Québec, Canada; 2Laboratoire de toxicologie, Institut national de santé publique du Québec (INSPQ), Québec, Canada

Background. Bone strength in Inuit people appears lower than that of non-Aboriginals. Inuit are exposed to persistent organic pollutants including dioxin-like compounds (DLCs) through their traditional diet that comprises predatory fish and marine mammal fat. Results from experimental and population studies suggest that some DLCs can alter bone metabolism and increase bone fragility.

Objective. This cross-sectional descriptive study was conducted to examine the relationship between the stiffness index (SI) and plasma concentrations of total DLCs or specific dioxin-like polychlorinated biphenyls (DL-PCBs) in Inuit women of Nunavik (Northern Quebec, Canada).

Methods. SI was determined by ultrasonography at the right calcaneus of 194 Inuit women aged 35–72 years who participated to Qanuippitaa? How Are We? Nunavik Inuit Health Survey in 2004. Plasma total DLC levels were quantified by measuring the aryl hydrocarbon receptor–mediated transcriptional activity elicited by plasma sample extracts in a cell-based reporter gene assay. Plasma concentrations of DL-PCBs nos. 105, 118, 156, 157, 167 and 189 were measured by gas chromatography–mass spectrometry. We used multiple linear regression analyses to investigate relations between total DLCs or specific DL-PCBs and SI, taking into consideration several potential confounders.

Results. Neither total plasma DLCs nor specific DL-PCBs were associated with SI after adjustment for several confounders and covariates.

Conclusion. Our results do not support a relation between exposure to DLCs and bone strength measured by ultrasonography in Inuit women of Nunavik.

Keywords: bone strength; stiffness index; dioxin-like compounds; polychlorinated biphenyls; Inuit women

Received: 13 March 2013; Revised: 1 May 2013; Accepted: 1 May 2013; Published: 29 May 2013
stiffness index (SI) value was 9.5% lower than that of southern Quebec Caucasian women (13).

It was hypothesized that the osteological features of Inuit could be related to their diet rich in animal proteins, phosphorus and nitrogen and low in calcium (3,4,14), or to genetic factors, sun exposure and cultural factors (15). Smoking, chronic use of oral steroids and the low dietary calcium intake were identified as the main risk factors for low bone mineral density (BMD) measured at the calcaneus in Alaska Native women (16).

In the study by Côté et al. (13), plasma concentrations of PCB-156, a mono-ortho substituted PCB congener displaying some affinity for the aryl hydrocarbon receptor (AhR), were negatively associated with calcaneal QUS parameters in Greenlandic Inuit women (13). Environmental chemicals that can bind the AhR are referred to as dioxin-like compounds (DLCs). DLCs are lipophilic and persistent compounds that are biomagnified in food chains; the main source of exposure to DLCs in human populations is the consumption of fat from contaminated animals (17). Inuit are exposed to DLCs mainly through their consumption of marine mammals as part of their traditional diet (2,18). DLCs induce antioestrogenic activity in bone tissue (19) and therefore could be involved in BMD reduction. Results of in vitro studies (20) and experimental studies in rats suggest that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the most potent DLC, affects bone metabolism and increases bone fragility (21,22). The relation between exposure to DLCs and bone quality, whether assessed by BMD or QUS parameters, has seldom been investigated in humans. The few studies available focused on specific dioxin-like polychlorinated biphenyls (DL-PCBs) and did not consider total DLC exposure (13,23,24).

SI reflects the structural parameters and elastic properties of the calcaneus and provides complementary information to that of BMD on bone strength. Osteoporotic patients who are more at risk of fragility fracture generally exhibit lower QUS parameter values than healthy subjects (25).

The main objective of this study was to examine the relationship between total plasma concentrations of DLCs (measured using an AhR-responsive cell-based reporter gene assay) or specific DL-PCBs (measured by gas chromatography coupled to electron capture negative ion mass spectrometry) and SI measured by ultrasonography at the calcaneus of Inuit women from Nunavik.

Methods

Population

The Inuit Health Survey entitled “Qanuippitaa? How Are We?” was organized by the Nunavik Regional Board of Health and Social Services and took place from August 27 to October 1, 2004, in the 14 Inuit communities of Nunavik (located north of the parallel 55°N in Québec, Canada) (26).

The target population for the survey was the entire population living permanently in Nunavik (9,632 inhabitants according to the 2001 Canadian census), with the following exclusions: (a) households where there was no adult Inuit aged 18 years and above; and (b) residents of collective dwellings (houses, hotels, nursing homes, hospitals and prisons). The target population represented 91% of the total population of Nunavik (26). The survey plan was a complex 2-stage stratified random sampling. The first stage was the selection of a random sample of private Inuit households stratified by community, with proportional allocation according to the community size. In the second stage, all eligible individuals living in these households were asked to participate in the survey. Among the 677 eligible households, 521 agreed to participate in the survey, which represents a total weighted response rate of 77.8%. These 521 houses have generated 2,550 individuals (26).

Participants answered a series of questionnaires available in English and Inuktitut that were administered by the research staff. Those aged 18–74 years also participated in a clinical session, which involved collection of blood samples and anthropometric measurements. All women aged 35–74 years who responded to the household questionnaire were eligible for QUS measurement. Among the 317 eligible women, 207 (aged 35–72 years) underwent QUS measurement. The weighted mean proportion of participants to this measure was therefore 65.5% and the global weighted response rate was 51% (26). Among the 207 participants, 12 of them were excluded (3 were not Inuit, 8 had no plasma DLC concentration and 2, including 1 without DLC value, were pregnant at the time of the study). Therefore, 195 Inuit women completed the study.

The project was approved by the Comité d’éthique de la recherche de l’Université Laval and the Comité d’éthique de santé publique du Québec. Participation in the study was voluntary and each participant signed a consent form. All information regarding the participants was kept strictly confidential.

Measurements and analyses

Bone measurements

SI was measured at the right calcaneus of participants using the portable ultrasound instrument Achilles Insight (GE Healthcare Lunar, Madison, WI, USA) (27). SI value was calculated automatically by the instrument from 2 QUS parameters, the speed of sound (SOS, m/s) and the broadband ultrasound attenuation (BUA, dB/MHz), using the formula from the manufacturer: 

$$SI\% = \frac{(0.67*BUA) + (0.28*SOS)}{420}.$$
The inspection of the instrument membranes was performed daily before the first measurement of the day, followed by a quality control test. The instrument was calibrated daily using the bone-mimicking phantom provided by the manufacturer. The accuracy was assessed

*in vitro* based on 36 repeated measurements conducted with the phantom of the manufacturer; the average coefficient of variation (CV) for SI was 0.15%.

**Anthropometric measures**

Body weight (kg; balance beam scale) and height (cm) were determined by research nurses using standardized techniques.

**Laboratory analyses**

Fasting blood samples were processed within 2 hours of collection. Samples collected in tubes containing EDTA as the anticoagulant were centrifuged, the plasma transferred into glass vials (Supelco) pre-washed with hexane and stored frozen at -20°C. Samples were shipped to the *Laboratoire de Toxicologie* of the *Institut National de Santé Publique du Québec* (INSPQ, Québec, Canada), where total DLCs and DL-PCB analyses were conducted.

The preparation of purified extracts for PCBs and AhR-mediated transcriptional activity analyses was previously described (28). An AhR-responsive cell-based reporter gene (luciferase) assay was used to measure the transcriptional activity elicited by plasma sample extracts. Total plasma DLC concentration was interpolated using a TCDD standard curve, and results were expressed in pg TCDD-equivalents (EQ)/L.

Data on the precision and relative accuracy of the AhR-responsive bioassay were obtained through the quantification of the NIST SRM (standard reference material) 1589a (National Institute of Standards and Technology, Gaithersburg, MD, USA) sample. The toxic equivalent concentration of this reference sample, calculated as the toxic equivalency factor-weighted sum of the certified (or reference) concentrations of PCDDs, PCDFs, non-ortho PCBs and mono-ortho PCBs was 189.1 pg/L. One NIST SRM 1589a per analytical batch (n = 30) was analysed, and a mean transcriptional activity of 170.7 pg TCDD-EQ/L and a CV of 26% was obtained. The apparent bias of the reporter gene bioassay was -9.7%. The limit of detection (LOD) was 30 pg TCDD-EQ/L (28).

Purified extracts were analysed for 44 PCB congeners, including 6 DL-PCBs (nos. 105, 118, 156, 157, 167 and 189), by gas chromatography coupled to electron capture negative ion mass spectrometry (28,29). The LOD for the DL-PCBs was 10 ng/L. Between-day CVs based on repeated measures of the NIST SRM 1589a ranged between 5.3 and 11.1% depending on the congener.

Concentrations of total cholesterol (TC) and total triglycerides (TGs) in plasma samples were determined by enzymatic methods at the *Centre de recherche sur les maladies lipidiques* (Centre de recherche CHU de Québec, QC, Canada). The total plasma lipid (TL) concentration was calculated from TC and TG concentrations (all of them expressed as g/L) by using the following formula (30): TL = 2.27 TC + TG + 0.623.

The fatty acid composition of phospholipids in erythrocyte membranes was also determined at the *Centre de recherche sur les maladies lipidiques* according to the method previously described (28). Polyunsaturated fatty acid (PUFA) content was expressed as the percentage of all fatty acids in membrane phospholipids. Total omega-3 PUFAs comprise the following fatty acids: α-linolenic acid (C18:3n-3), docosapentaenoic acid (C22:5n-3), docosahexaenoic acid (C22:6n-3), eicosapentaenoic acid (C20:5n-3), C18:4n-3, C20:3n-3 and C20:4n-3. Total omega-6 PUFAs refer to the sum of linoleic acid (C18:2n-6), arachidonic acid (C20:4n-6), C18:3n-6, C20:2n-6, C20:3n-6, C22:2n-6, C22:4n-6 and C22:5n-6.

Methods for quantifying blood levels of toxic metals (lead, mercury) as well as plasma retinol and vitamin D concentrations have been published elsewhere (26,31).

**Questionnaires**

Questionnaires were used to document socio-demographic variables (date and place of birth; level of education: none or primary/secondary and higher), lifestyle habits (smoking during the last year, yes/no) and gynaecological history (menopausal status, postmenopausal/non-menopausal; parity, yes/no). Women were considered postmenopausal if they had no menstrual period for 1 year before their recruitment in the study. Medical files were consulted to document the use of calcium and vitamin D supplements (yes/no).

**Statistical analyses**

Descriptive statistics [mean, standard error (SE) of the mean, minimum, maximum for quantitative variables or numbers and percent per modality for categorical variables] were presented for our 195 participants.

DLC concentrations were below the LOD (30 pg TCDD-EQ/L) for 32 participants. In these cases, we imputed a value between 0 and the LOD selected by simple random sampling with replacement. Plasma concentrations of DL-PCBs nos. 105, 156, 157, 167 and 189 were below the LOD (10 ng/L) for 5, 3, 23, 19 and 68 participants, respectively. In these cases, we imputed a value equal to 5 ng/L (LOD/2).

Pearson’s correlation coefficients were calculated between SI and plasma levels of total DLCs or individual DL-PCB congeners. The relationships between total DLCs or DL-PCBs and SI were examined by multiple linear regression analyses. Two multivariate models were proposed. The models were adjusted for multiple confounders and covariates, including the total concentration of plasma lipids.

Multicollinearity diagnostics were performed for all independent variables. For continuous variables, the
normality, linearity and homoscedasticity of residuals were tested graphically and through hypothesis testing. Box–Cox procedures were used to resolve problems encountered with the hypotheses of normality and/or homoscedasticity in the multiple regression models for SI, which was subsequently log-transformed.

Populational weight was calculated by the Institut de la Statistique du Québec (ISQ) and used to obtain all estimates, while SEs were computed using the bootstrap procedure (26). ISQ considered that 500 sub-samples were sufficient to provide bootstrap weights for the survey.

A p-value < 0.05 in the bilateral situation was considered statistically significant. Statistical analyses were performed with SAS version 9.2 software (SAS Institute Inc., Cary, NC, USA) and SUDAAN version 10.0 software.

Results

Characteristics of participants

The main characteristics of the participants are listed in Table I. Inuit women were aged between 35 and 72 years and were predominantly non-menopausal. A majority of participants had children, a low level of education and were smokers.

Only 10% had taken calcium and vitamin D supplements during the last 12 months. Forty-four percent had

| Table I. Characteristics of Inuit women from Nunavik |
|-----------------------------------------------|
| Characteristic | N\textsuperscript{a} (N\textsuperscript{b}) | AM\textsuperscript{c} (SE) | Range | GM\textsuperscript{d} (SE) |
| SI (%) | 1,140 (195) | 78.7 (1.0) | 39–135 |
| DLCs (pg TCDD-EQ/L) | 1,140 (195) | 120.4 (7.1) | 0.7–570 |
| DL-PCB 105 (ng/L) | 1,140 (195) | 115.0 (7.0) | 5–620 |
| DL-PCB 118 (ng/L) | 1,140 (195) | 582.7 (35.5) | 22–3,000 |
| DL-PCB 156 (ng/L) | 1,140 (195) | 163.3 (13.0) | 5–1,800 |
| DL-PCB 157 (ng/L) | 1,140 (195) | 60.4 (4.8) | 5–520 |
| DL-PCB 167 (ng/L) | 1,140 (195) | 55.2 (3.8) | 5–460 |
| DL-PCB 189 (ng/L) | 1,140 (195) | 25.6 (2.2) | 5–270 |
| ΣDL-PCBs\textsuperscript{e} (ng/L) | 1,140 (195) | 1,002 (59) | 47–4,818 |
| Mercury (nmol/L) | 1,140 (195) | 132.1 (6.7) | 4.9–760 |
| Lead (μmol/L) | 1,140 (195) | 0.28 (0.01) | 0.04–1.5 |
| Age (years) | 1,140 (195) | 48.6 (0.5) | 35–72 |
| Weight (kg) | 1,124 (192) | 66.6 (1.0) | 37.6–118 |
| Height (cm) | 1,140 (195) | 152.3 (0.3) | 142–164 |
| Omega-3 PUFAs (%) | 1,140 (195) | 11.9 (0.2) | 1.7–19.5 |
| Omega-6 PUFAs (%) | 1,140 (195) | 23.3 (0.3) | 12.6–32.4 |
| Retinol (μmol/L) | 1,111 (191) | 2.16 (0.04) | 1.04–3.58 |
| Vitamin D (nmol/L) | 1,134 (194) | 30.1 (0.7) | 5.9–67.5 |
| Total plasma lipids (g/L) | 1,135 (194) | 6.4 (0.1) | 4.1–11.4 |
| Menopausal status | 1,139.7 | 195 |
| Postmenopausal | 486.4 (42.7) | 79 |
| Non-menopausal | 653.3 (57.3) | 116 |
| Level of education | 1,093.3 | 191 |
| None or primary school | 590.7 (54.0) | 103 |
| Secondary or higher | 502.6 (46.0) | 88 |
| Supplement use\textsuperscript{b} | 1,139.6 | 195 |
| Yes | 115.4 (10.1) | 19 |
| No | 1,024.2 (89.9) | 176 |
| Tobacco use | 1,131.4 | 193 |
| Yes | 827.3 (73.1) | 144 |
| No | 304.1 (26.9) | 49 |
| Parity | 1,123.4 | 192 |
| Yes | 1,057.7 (94.1) | 182 |
| No | 65.7 (5.9) | 10 |

\textsuperscript{a}Weighted and rounded size; \textsuperscript{b}sample size; \textsuperscript{c}arithmetic mean; \textsuperscript{d}geometric mean; \textsuperscript{e}sum of DL-PCB nos. 105, 118, 156, 157, 167 and 189; \textsuperscript{f}weighted size; \textsuperscript{g}calcium and vitamin D supplements in the last 12 months.
a plasma vitamin D level considered as critical (<27.5 mmol/L) (32); 74% displayed inadequate levels (<37.5 mmol/L), whereas 94% showed levels considered to be minimal (<5.0 mmol/L) (33). Plasma concentrations of retinol (vitamin A) were normal in 70% of Inuit women (300–700 mg/L, 1.05–2.44 mmol/L) (34); <1% had a level below the normal range and 30% were above.

With regard to blood mercury levels, 98% of Inuit women exceeded the maximum blood mercury level of 16 nmol/L observed in women from the Quebec City area (35), whereas 50% exceeded Canada’s alert level of 99.7 nmol/L (36). The maximum blood lead level of 0.32 µmol/L noted in women from the Quebec City area (35) was exceeded by 32% of participants, while 11% exceeded Canada’s alert level of 0.48 µmol/L (37).

**Pearson’s correlation coefficients (r)**

SI values (log-transformed) were negatively correlated with total DLCs, DL-PCBs and age (r = −0.34 to −0.58, p < 0.0001). Total DLCs and the 6 DL-PCBs were intercorrelated (r = 0.58–0.69, p < 0.0001); all of them were positively correlated with age (r = 0.58–0.75, p < 0.0001).

**Results from multivariate analyses**

**Main exposure variables**

In multivariate models adjusted for a larger number of confounding factors and covariates (model 1; Table II), the significant associations between DL-PCB nos. 156, 157, 167 and 189 and SI (log) observed in models adjusted only for age and TLs (model 2) were no longer significant.

**Factors significantly associated with SI (log)**

In multivariate models adjusted for 15 confounders and covariates (model 1), 3 variables were found to be associated with SI. Age was negatively associated with SI in all models. Taking supplements (calcium and vitamin D) was negatively associated with SI in models where the main exposure variable was either total DLCs, DL-PCB 105, DL-PCB 118, DL-PCB 156, DL-PCB 167 or the sum of DL-PCBs. The omega-3 PUFA content of erythrocyte’s membrane phospholipids was positively associated with SI in models comprising either total DLCs, DL-PCB 156, DL-PCB 167 or the sum of DL-PCBs as the main exposure variable. Generally speaking, SI (log) decreased with age and with supplement (calcium and vitamin D) use and SI values (log) increased with the content of omega-3 PUFAs in erythrocyte membrane phospholipids (data not shown).

**Discussion**

We have investigated the relation between exposure to total DLCs or specific DL-PCBs and bone strength assessed by QUS in a representative sample of Inuit women from Nunavik. Neither the total DLC measure obtained using the reporter gene bioassay nor specific DL-PCBs congeners were associated with SI in multivariate models.

To the best of our knowledge, this is the first study to investigate the relationship between exposure to DLCs measured globally using an AhR-responsive cell-based reporter gene bioassay and bone quality, either assessed by QUS parameters or BMD. In contrast, 3 studies investigated exposure to DL-PCBs as a risk factor of lower bone quality and they yielded conflicting results.

In the study by Glynn et al. (23) conducted among Swedish men from the general population (n = 115, aged 40–75 years), a positive association of borderline significance (β = 0.0044, p = 0.05) was found between DL-PCB 167 serum concentrations and total body BMD measured by dual-energy X-ray absorptiometry (DXA), after adjustment for several confounding factors. However, the authors found no relationship between

Table II. Results of explanatory multiple linear regression analyses: SI (log) models

| Contaminant | Main exposure variables | Model 1<sup>a</sup> N<sup>d</sup> = 1,041 (N<sup>d</sup> = 180) | Model 2<sup>b</sup> N<sup>d</sup> = 1,135 (N<sup>d</sup> = 194) |
|-------------|-------------------------|------------------------------------------|------------------------------------------|
|             | R²                      | Regression coefficient (SE)<sup>c</sup> | p-Value<sup>d</sup>                      | R²                      | Regression coefficient (SE)<sup>c</sup> | p-Value<sup>d</sup> |
| DLCs (pg TCDD-EQ/L) | 0.4184 | 1.6468 (1.3199) | 0.2128 | 0.3303 | −0.1245 (1.5045) | 0.9341 |
| DL-PCB 105 (ng/L) | 0.4170 | 1.8651 (1.7705) | 0.2926 | 0.3307 | −0.5484 (1.7947) | 0.7601 |
| DL-PCB 118 (ng/L) | 0.4163 | 0.3552 (0.4085) | 0.3850 | 0.3339 | −0.3153 (0.3618) | 0.3840 |
| DL-PCB 156 (ng/L) | 0.4141 | −0.1520 (0.7529) | 0.8401 | 0.3462 | −1.5856 (0.6564) | 0.0161 |
| DL-PCB 157 (ng/L) | 0.4242 | −4.5409 (2.3586) | 0.0548 | 0.3719 | −7.1843 (1.6857) | <0.0001 |
| DL-PCB 167 (ng/L) | 0.4143 | −0.9897 (3.2387) | 0.7601 | 0.3499 | −6.5369 (2.6521) | 0.0140 |
| DL-PCB 189 (ng/L) | 0.4217 | −7.7779 (5.0742) | 0.1260 | 0.3673 | −14.2291 (4.2063) | 0.0008 |
| ΣDL-PCBs<sup>e</sup> (ng/L) | 0.4212 | 0.0712 (0.2391) | 0.7600 | 0.3422 | −0.3521 (0.2110) | 0.0958 |

<sup>a</sup>Model adjusted for age, total plasma lipids, menopausal status, education level, supplement use (calcium and vitamin D), blood mercury levels, blood lead levels, omega-3 PUFA, omega-6 PUFA, vitamin A (retinol), vitamin D, tobacco use, parity, height, weight; <sup>b</sup>model adjusted for age and total plasma lipids; <sup>c</sup>weighted and rounded size; <sup>d</sup>sample size; <sup>e</sup>the values of the regression coefficients and standard errors were multiplied by 10<sup>4</sup>; <sup>f</sup>Wald Chi square test with Satterthwaite correction for the degrees of freedom; <sup>g</sup>sum of DL-PCBs nos. 105, 118, 156, 157, 167 and 189.
DL-PCB 167 serum levels and QUS parameters (BUA and SOS) measured at the left calcaneus. Serum levels of DL-PCBs nos. 105, 118 and 156 were neither associated with QUS parameters nor with BMD measured at the spine, femoral neck or total body level (23).

In multivariate regression analyses, Côté et al. (13) observed that plasma DL-PCB 156 concentrations were negatively associated with QUS bone parameters in peri- and postmenopausal Inuit women from Nuuk, Greenland (SOS model: \( \beta = -22.68, p = 0.014 \); BUA model: \( \beta = -8.12, p = 0.028 \); SI model: \( \beta = -11.95, p = 0.009 \)). However, residual confounding may be present, because the models were only adjusted for 4 factors (age, weight, oral contraceptives and hormone replacement therapy). In the same study, DL-PCB 105 and DL-PCB 118 plasma levels were not associated with QUS parameters (13).

Hodgson et al. (24) identified in the multiple regression models a significant negative relationship (\( \beta = -0.00024, p = 0.002 \)) between serum DL-PCB 118 concentrations and BMD measured by DXA at the forearm (radius and ulna, non-dominant arm) of 154 Swedish men (60–81 years) participating in the OSCAR cohort. In contrast, among 167 women enrolled in the same study, DL-PCB 118 levels were positively associated with BMD (\( \beta = 0.00008, p = 0.045 \)). No relationship between levels of other DL-PCBs (nos. 105, 156, 157 and 167) and BMD was observed. The authors pointed out problems such as an insufficient statistical power and a low proportion of the variance in BMD explained by the models (24).

Mean plasma concentrations of DLCs in Inuit women from Nunavik were lower than those reported in Inuit women from 6 regions of Greenland using a similar bioassay (38). Geometric mean (GM) concentrations of specific DL-PCB congeners in plasma samples of Inuit women were greater than those reported for women aged 40–79 years who participated in the Canadian Health Measures Survey in 2007–2009, and who were representative of the general Canadian population (39).

The mean SI value of 78.7% reported here for Nunavik women was lower than that of 91.5% measured using the same instrument in 249 Cree women of comparable age (mean age of 48 years) from East James Bay (Northern Quebec) (40).

Our study has several strengths. Firstly, the data used in this work were obtained from a large health survey conducted in the Inuit population of Nunavik, a unique population with a relatively high exposure to persistent organic pollutants. Our population sample was likely representative of all women aged 35–72 years of Nunavik, because of the study design, the recruitment strategy and the weighting scheme that takes into account non-response and refusals to participate. Secondly, we considered a large number of confounding factors and covariates, some of them investigated for the first time (omega-3 and omega-6 PUFAs, retinol, mercury). Thirdly, measurement biases on the dependent variable or exposure variables are unlikely. QUS parameters, anthropometric measures and biological sampling were all performed by research nurses using standardized techniques. DL-PCBs and total DLC analyses were performed at the Laboratoire de Toxicologie of the INSPQ, which is accredited under ISO 17025 by the Standards Council of Canada. QA/QC measures were all within acceptable ranges.

However, this study has some limitations. Firstly, the main methodological limitation is its cross-sectional design, with exposure and the dependent variable measured at the same time, such that the temporal sequence of cause and effect cannot be determined. However, due to the fact that DLCs and DL-PCBs accumulate in the body with age, plasma concentrations in Inuit women reflect their exposure throughout their lifetime. Secondly, the participation rate of women aged 35–72 years at QUS measurements was relatively small, which could potentially lead to a selection bias. However, this bias is quantitatively unimportant, since it is unlikely that the characteristics of the women included in the study would be different from those of all eligible women. Regarding the non-response and refusal to participate in the study, it is unlikely that the non-participants would have different levels in plasma DLCs, DL-PCB congeners or SI values than those of the participants; Inuit were recruited for a general health survey and not specifically for the purpose of our study on bone health. Thirdly, the number of participants was relatively small, limiting our capacity to observe an association between DLC concentrations determined by the reporter gene assay and QUS parameters, especially considering that the bioassay is relatively imprecise compared to analytical chemistry based data. Lastly, the reporter gene assay does not allow the identification of specific compounds involved in triggering the transcriptional response. The bioassay provides a global measure of activity for the complex mixture of persistent organic pollutants extracted from plasma samples (i.e. PCDDs, PCDFs and DL-PCBs). Other environmental contaminants such as brominated dioxins, polychlorinated terphenyls, polychlorinated naphthalenes can also interact with the AhR-signalling pathway and may have contributed to the global response measured.

In conclusion, despite being exposed to DLCs through their traditional diet, we found no association between this exposure and bone strength, assessed by QUS, in Inuit women of Nunavik.

Acknowledgements

The authors acknowledge the support of Fonds de Recherche du Québec-Santé (FRQ-S) Environmental Health Research Network.
Conflict of interest and funding

Funding for the Nunavik Health Survey was provided by the Northern Contaminants Program (Aboriginal Affairs and Northern Development Canada), Nunavik Regional Board of Health, Quebec’s Ministry of Health and Social Services, and ArcticNet Network of Centres of Excellence of Canada. A.-C. P. is the recipient of a Doctoral Training Award from FRQ-S and a doctoral scholarship from Nasivik – Centre for Inuit Health and Changing Environments.

References

1. Riget F, Dietz R, Vorkamp K, Johansen P, Muir D. Levels and spatial and temporal trends of contaminants in Greenland biota: an updated review. Sci Total Environ. 2004;331:29–52.
2. Bjerregaard P, Dewailly E, Ayotte P, Pars T, Ferron L, Mulvad G. Exposure of Inuit in Greenland to organochlorines through the marine diet. J Toxicol Environ Health A. 2001;62:69–81.
3. Mazess RB, Mather W. Bone mineral content of North Alaskan Eskimos. Am J Phys Anthropol. 1974;27:916–25.
4. Mazess RB, Mather WE. Bone mineral content in Canadian Eskimos. Hum Biol. 1975;47:44–63.
5. Pawson IG. Radiographic determination of excessive bone loss in Alaskan Eskimos. Hum Biol. 1974;46:369–80.
6. Thompson DD, Gunnness-Hey M. Bone mineral-osteon analysis of Yupik-Inupiaq skeletons. Am J Phys Anthropol. 1981; 55:1–7.
7. Thompson DD. Age changes in bone mineralization, cortical thickness, and Haversian canal area. Calcif Tissue Int. 1980; 31:5–11.
8. Thompson DD, Salter EM, Laughlin WS. Bone core analysis of Baffin Island skeletons. Arctic Anthropol. 1981; XVIII: 87–96.
9. Harper AB, Laughlin WS, Mazess RB. Bone mineral content in St. Lawrence Island Eskimos. Hum Biol. 1984;56:63–78.
10. Richman EA, Ortnier DJ, Schultzer-Ellis FP. Differences in intracortical bone remodelling in three aboriginal American populations: possible dietary factors. Calcif Tissue Int. 1979; 28:209–14.
11. Ericksen MF. Patterns of microscopic bone remodeling in three aboriginal American populations. In: Browman DL, editor. Early Native Americans: prehistoric demography, economy, and technology. The Hague: Mouton; 1980. p. 239–70.
12. Richman RA, Ortnier DJ. Intracortical bone remodelling in three aboriginal American populations: possible dietary factors in differences. Paper presented to the 47th Annual Meetings of the American Association of Physical Anthropologists, Toronto; 1978.
13. Côôte S, Ayotte P, Dodin S, Blanchet C, Mulvad G, Petersen HS, et al. Plasma organochlorine concentrations and bone ultrasound measurements: a cross-sectional study in peri- and postmenopausal Inuit women from Greenland. Environ Health. 2006;5:33.
14. Ellestad-Sayed J, Hildes JA, Schaefer O, Lobban MC. Twenty-four hour urinary excretion of vitamins, minerals and nitrogen by Eskimos. Am J Clin Nutr. 1975;28:1402–7.
15. Martin RB, Burr DB, Schaffler MB. Effects of age and sex on the amount and distribution of mineral in Eskimo tibiae. Am J Phys Anthropol. 1985;67:371–80.
16. Filner JJ, Krohn KD, Lapidus JA, Becker TM. Risk factors for osteoporosis in Alaska Native women: a cross-sectional survey. Alaska Med. 2002;44:8–13.
17. Lorber M, Patterson D, Huwe J, Kahn H. Evaluation of background exposures of Americans to dioxin-like compounds in the 1990s and the 2000s. Chemosphere. 2009;77:640–51.
18. Dewailly E, Ayotte P, Bruneau S, Laliberté C, Muir DC, Norstrom RJ. Inuit exposure to organochlorines through the aquatic food chain in arctic quebec. Environ Health Perspect. 1993;101:618–20.
19. Partridge NC, Fiacco GI, Walling HW, Barmina OY, Jeffrey JJ, Ruhi MF. Effects of dioxin and estrogen on collagenase-3 in UMR 106-01 osteosarcoma cells. Arch Biochem Biophys. 2000;382:182–8.
20. Carpi D, Korkalainen N, Airola L, Fanelli R, Hakansson H, Muhonen V, et al. Dioxin-sensitive proteins in differentiating osteoblasts: effects on bone formation in vitro. Toxicol Sci. 2009;108:330–43.
21. Finnäll MA, Zioupos P, Herlin M, Miettinen HM, Simanainen U, Hakansson H, et al. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on bone material properties. J Biomech. 2010;43:1097–103.
22. Lind PM, Wejheden C, Lundberg R, Alvarez-Lloret P, Hermens SA, Rodriguez-Navarro AB, et al. Short-term exposure to dioxin impairs bone tissue in male rats. Chemosphere. 2009;75:680–4.
23. Gyllen AW, Michaelsson K, Lind PM, Wolk A, Aune M, Atuma S, et al. Organochlorines and bone mineral density in Swedish men from the general population. Osteoporos Int. 2000;11:1036–42.
24. Hodgson S, Thomas L, Fattore E, Lind PM, Alfen T, Hellström L, et al. Bone mineral density changes in relation to environmental PCB exposure. Environ Health Perspect. 2008;116:1162–6.
25. Danese RD, Licata AA. Ultrasound of the skeleton: review of its clinical applications and pitfalls. Curr Rheumatol Rep. 2001;3:245–8.
26. Rochette L, Blanchet C. Nunavik Inuit Health Survey 2004 Qanuippitaa? How are we? Methodological Report: Institut national de santé publique du Québec and Nunavik Regional Board of Health and Social Services; 2007, 338 p [cited 2012 Dec 20]. Available from: http://www.inspq.qc.ca/pdf/publications/692_esi_methodological_report.pdf.
27. GE Medical Systems Lunar, Madison Wisconsin. Manuel de l’opérateur Achilles InSight/Express. 2006 [cited 2010 Jun 10]. Available from: http://www.gehealthcare.com.
28. Medehouenou TC, Larochelle C, Dumas P, Dewailly E, Ayotte P. Determinants of AhR-mediated transcriptional activity induced by plasma extracts from Nunavik Inuit adults. Chemosphere. 2010;80:75–82.
29. Sandanger TM, Sinotte M, Dumas P, Marchand M, Sandau CD, Pereg D, et al. Plasma concentrations of selected organobromine compounds and polychlorinated biphenyls in postmenopausal women of Quebec, Canada. Environ Health Perspect. 2007;115:1429–34.
30. Phillips DL, Pirkle JL, Burse VW, Bernert JT Jr., Henderson LO, Needham LL. Chlorinated hydrocarbon levels in human serum: effects of fasting and feeding. Arch Environ Contam Toxicol. 1989;18:495–500.
31. Plante C, Blanchet C, Rochette L, O’Brien HT, Prevalence of anemia among Inuit women in Nunavik, Canada. Int J Circumpolar Health. 2011;70:154–65.
32. Institute of Medicine (IOM). Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. 1997 [cited 2011 Jan 3]. Available from: http://www.nap.edu/openbook.php?record_id=5776&page=250.
33. The Journal of The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17:25–54.
34. Cruz JA, Moreiras-Varela O, van Staveren WA, Trichopoulou A, Roszkowski W. Intakes of vitamins and minerals. Eur J Clin Nutr. 1991;45:121–38.
35. LeBlanc A, Lapointe S, Beaudet A, Côté I, Dumas P, Labrecque F, et al. Étude sur l’établissement de valeurs de référence d’éléments traces et métaux dans le sang, le sérum et l’urine de la population de la grande région de Québec. Direction toxicologie humaine, Direction risques biologiques, environnementaux et occupationnels, Institut National de Santé Publique du Québec; 2004, 113 p [cited 2013 Jan 15]. Available from: http://www.inspq.qc.ca/pdf/publications/289-ValeursReferenceMetaux.pdf.
36. Health Canada Mercury Issues Task Force. Mercury. Your health and the environment. A resource tool. Ottawa: Health Canada; 2004. 54 p.
37. Health Canada. Update of evidence for low-level effects of lead and blood lead intervention levels and strategies—final report of the working group. (ACEOH) environmental health directorate. Ottawa: Health Canada, editor; 1994. 118 p.
38. Bonefeld-Jørgensen EC, Long M. Dioxin-like activity in the blood of Greenlandic Inuit and Danish women: a pilot study. Int J Circumpolar Health. 2010;69:181–94.
39. Santé Canada. Rapport sur la biosurveillance humaine des substances chimiques de l’environnement au Canada. Résultats de l’Enquête canadienne sur les mesures de la santé Cycle 1 (2007 à 2009), 2010, 300 p [cited 2012 Dec 14]. Available from: http://www.hc-sc.gc.ca/ewh-senat/alt_formats/hecs-esc/pdf/pubs/contaminants/chms-ecms/report-rapport-fra.pdf.
40. Paunescu AC. Les composés dioxin-like mesurés par DR-CALUX et les paramètres osseux évalués par ultrasonographie chez les femmes criees et inuites du Nord-du-Québec et du Groenland [Ph.D. thesis]. Québec: Université Laval; 2012.

*Pierre Ayotte
Centre de recherche du CHU de Québec and INSPQ
945, Avenue Wolfe
Québec, QC, Canada G1V 5B3
Tel: 1-418-650-5115 ext. 4654
Fax: 1-418-654-2148
Email: pierre.ayotte@inspq.qc.ca